Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I StudyNingning Zhang, Xiaolu Tao, Yanxia He et al.|Clinical Cancer Research|2025Cited by 4
Efficacy and safety of HBM4003 combined with toripalimab in refractory neuroendocrine neoplasms: a multicenter, phase II studyPanpan Zhang, Ming Lü, Kai Chen et al.|EClinicalMedicine|2025Cited by 3
Data from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I StudyNingning Zhang, Xiaolu Tao, Tian Liu et al.|Unknown|2025Cited by 0
Supplementary Figure S1 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I StudyNingning Zhang, Xiaolu Tao, Tian Liu et al.|Unknown|2025Cited by 0
Supplementary Figure S4 from Porustobart (HBM4003) plus Toripalimab as Second-Line Therapy in Patients with Advanced Hepatocellular Carcinoma: A Multicenter, Open-Label, Phase I StudyNingning Zhang, Xiaolu Tao, Tian Liu et al.|Unknown|2025Cited by 0